Cambridge, MA— Mediar Therapeutics, a biotechnology company pioneering a new approach to fibrosis treatment, announced that it has raised $105M in funding. The round was led by Eli Lilly and Company, Pfizer, Sofinnova Partners, Mission BioCapital, Mass General Brigham Ventures, and Bristol Myers Squibb with additional investments from Pureos Bioventures and Gimv.

The funding will be used to further Mediar’s research into its breakthrough approach to halting fibrosis at the source – the fibrotic mediators that drive disease progression. Founded by Rahul Ballal based on a deep understanding of the complex science underlying fibrosis onset and progression, Mediar is derisking the path forward for developing novel therapies for this serious condition with reliable biomarkers and familiar modalities.

“This is an incredibly exciting time for Mediar as we move closer to our goal of advancing treatments for patients with fibrosis around the world," said Rahul Ballal, CEO of Mediar Therapeutics. "We are grateful for our investors’ support as we continue our mission to make impactful improvements in patient outcomes."